Business Information
Regenerative Medical Solutions (RMS) is a biotechnology company focused on transforming diabetes treatment through innovative stem cell technology. Based in Madison, WI, RMS specializes in developing stem cell-derived Islet-Like Clusters (ILCs) for both continued research purposes and therapeutic applications. Our proprietary technology, developed over 15 years of research, enables scalable production of ILCs that function like human pancreatic islet cells, offering new hope for diabetes treatment. RMS is dedicated to advancing diabetes care through cutting-edge research, product development, and clinical solutions.

RMS research center in Madison Wisconsin researching a cure for diabetes

Dr. Dena E. Cohen is the Chief Scientific Officer of RMS.

Regenerative Medical Solutions research center in Madison Wisconsin

Healthcare professional showing improvement to insulin levels in a diabetes patient

Healthcare panel discussion about diabetes cures sponsored by Regenerative Medical Solutions

Figure 2 from an RMS scientific publication

Imaging of islet-like cluster cells

Dr. Jon Odorico is the Chief Scientific Officer and the Scientific Founder of RMS.

Figure 2 from an RMS scientific publication

Figure 3 from an RMS scientific publication

Figure 4 from an RMS scientific publication

Healthy eating of veggies for a healthy diet to improve diabetes

Scientist testing islet like cluster cells from an RMS ILC Cell kit

Microimaging novel technology to transform stem cells into insulin producing cells

Stem cell-derived pancreatic islet clusters

Opening Times
Mon-Fri 9am-5pm, Sat-Sun Closed

Email Addresses
info@regenmedsolutions.com

Products:
ILC Cell Technology – Human iPSC-derived Islet-Like Clusters (ILCs) for research., ILC Cellular Therapeutics – Stem cell-based therapeutic candidates in pre-clinical development., ILC Cells Kit – Cryopreserved single-cell ILCs for diabetes research, discovery, and toxicity tests., Allogeneic ILC Cellular Therapeutics – Stem cell therapy using donor-derived iPSCs to treat diabetes

Services:
Diabetes Research Tools – Offering ILC cells for in vitro studies, drug research, and toxicity tests, Cell Therapy Development – Advancing autologous and allogeneic stem cell therapies for diabetes, Stem Cell Differentiation – Developing proprietary methods to create pancreatic islet-like cells, Clinical Trial Preparation – Pre-clinical development for cellular therapeutics targeting diabetes.

Specialties:
Stem Cell Research – Focused on the differentiation of pluripotent stem cells into pancreatic islet, Diabetes Treatment Innovation – Developing novel therapies to restore insulin production in patients, Cellular Therapeutics – Pre-clinical development of autologous and allogeneic stem cell therapies., Pancreatic Islet Biology – Specializing in creating islet-like clusters that mimic human pancreatic, iPSC Technology – Utilizing induced pluripotent stem cells (iPSCs) for diabetes research and treatme, Drug Discovery Tools – Providing reliable, scalable ILC cells for research and testing., Toxicity Screening – Using ILC cells to screen for toxicity and efficacy in drug development.

Associations:
University of Wisconsin-Madison: Collaborates with stem cell pioneer Dr. James Thomson, Northwestern University: Advisor Harry M. Jansen Kraemer, Jr., is a Clinical Professor, University of California, San Francisco (UCSF): Advisor Dr. Peter G. Stock

Established:
2012

Map location Select here to view map

Editing or updating this listing

Update your details here if you are unaware of any log-in information for this listing.

Disclaimer

Opinions expressed within reviews are those of the individual author and are not the views or opinions of Lowi Ltd, My Local Services or any of its employees.

If you have an issue with any review comments then please fill in the review issue form and include as much detail as possible.

Incorrect data:
If you want to report incorrect information on this web page, then please contact us and outline the issue. We aim to resolve most problems within one business day.